Infectious Respiratory Disease Immunization Timeline: Children and Adolescents (Ages 6-17)

The best protection against many infectious respiratory illnesses is immunization. Immunizations can help provide protection, build our immune response, and can limit the severity, spread, and widespread threat of disease.

Last Updated 03/20/2025

Infectious Respiratory Disease Immunization Timeline: Babies and Young Children (Ages 2 Months-6 Years)

Last Updated 03/20/2025

The Benefits of Immunization for High-Risk Populations

Older adults, young children and people with certain health conditions are at greater risk for severe respiratory disease. Vaccines provide important protection.

Last Updated 03/12/2025

Pneumococcal Disease | Childhood | Vaccines

What to Know About Pneumococcal Vaccines for Children and Adolescents

Pneumococcal disease is dangerous for children and adolescents, and those under 5 years of age are especially at risk. Getting the pneumococcal vaccine helps prevent severe infections that can lead to hospitalization or even death.

Last Updated 03/06/2025

Pneumococcal Disease | Vaccines

What to Know About Pneumococcal Vaccines for Adults

Pneumococcal disease is caused by a bacterial infection and can result in many different types of infections, including pneumonia. Anyone can get pneumococcal disease, but certain people are at increased risk. The best way to help prevent pneumococcal disease is to get vaccinated.

Last Updated 03/06/2025

Vaccines

Vaccine Approval in the United States

Vaccine development follows the FDA’s gold-standard review process which includes research, multi-stage clinical trials, robust regulatory review and approvals, and ongoing safety monitoring once a vaccine becomes publicly available.

Last Updated 02/14/2025

Vaccines | Treatments

CVEEP 2024 Highlight Reel

Check out highlights from CVEEP’s resources, campaigns, events, and videos in 2024.

Last Updated 01/24/2025

RSV | Immunocompromised | Infectious Respiratory Diseases | Older Adult | Vaccines

RSV Vaccines: Insights for At-Risk and Older Adults

Last Updated 12/10/2024

Last year’s availability of respiratory syncytial virus (RSV) vaccines marked a critical step in science and public health. Previously, no widespread prevention option existed to protect those at increased risk for RSV, including older adults, from this serious infectious respiratory disease. In the year since RSV vaccines were first introduced, real world evidence has shown that they are effective in preventing serious illness for individuals 60 years and older. However, despite the progress made towards RSV prevention, RSV vaccine uptake continues to remain low in older adults.

As we continue into peak respiratory season and beyond, CVEEP hosted an expert-led conversation on updated risk-based RSV vaccine guidance for older adults, the value of vaccination for adults at highest risk for severe RSV disease, and other important considerations to help promote vaccine uptake across communities.

The discussion was moderated by Karyne Jones, President and Chief Executive Officer of the National Caucus and Center on Black Aging, a convener of CVEEP.

Infectious Respiratory Diseases | Immunocompromised | Older Adult | Treatments | Vaccines

Preparing for Respiratory Illness Season: A Guide for Long-term Care

Ahead of respiratory disease season this fall and winter, developing a care plan for vaccination, testing, and treatment can help protect loved ones in long-term care facilities from serious illness and make a potentially stressful time more manageable.

Last Updated 12/10/2024

Vaccines | COVID-19 | Flu | Infectious Respiratory Diseases

Posters: Stay Updated on COVID-19 and Flu Vaccines

Last Updated 12/10/2024